Rx Drug Ads: Number Of Side Effects, Price-Comparison Claims Impact Risk Perception
Commercials citing non-severe side effects dilute message, London study concludes; US FDA finds price comparison claims may cause physicians to think a drug's risks are less severe and that risk info is less prominent on mobile devices.
You may also be interested in...
Agency is considering whether drug broadcast ads should note only risks that are severe, serious or actionable; FDA study finds this limitation improves risk recall and recognition of benefits.
Flurry of new studies brings tally of FDA research projects on Rx drug promotion to 43; the 14 in progress and 7 pending peer review or recently published have a total cost of $15.5m.
New proposed rule says a manufacturer’s knowledge of the unapproved use of a product does not alone determine intended use. Former FDA lawyer says rule could set off fireworks over the scope of what the agency considers evidence of off-label use.